Sanctuary Advisors LLC Purchases Shares of 1,756 argenx SE (NASDAQ:ARGX)

Sanctuary Advisors LLC purchased a new stake in argenx SE (NASDAQ:ARGXFree Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 1,756 shares of the company’s stock, valued at approximately $755,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Blue Trust Inc. lifted its holdings in argenx by 620.0% in the 2nd quarter. Blue Trust Inc. now owns 72 shares of the company’s stock valued at $28,000 after acquiring an additional 62 shares during the last quarter. J.Safra Asset Management Corp lifted its holdings in argenx by 590.0% in the 2nd quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock valued at $30,000 after acquiring an additional 59 shares during the last quarter. GAMMA Investing LLC lifted its holdings in argenx by 420.0% in the 1st quarter. GAMMA Investing LLC now owns 78 shares of the company’s stock valued at $31,000 after acquiring an additional 63 shares during the last quarter. Mather Group LLC. acquired a new stake in argenx in the 1st quarter valued at about $38,000. Finally, Point72 Hong Kong Ltd acquired a new stake in argenx in the 2nd quarter valued at about $76,000. 60.32% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ARGX has been the subject of a number of analyst reports. William Blair reaffirmed a “market perform” rating on shares of argenx in a research note on Monday, June 17th. Robert W. Baird upped their price objective on shares of argenx from $490.00 to $515.00 and gave the company an “outperform” rating in a research note on Monday, July 29th. Evercore ISI upped their price objective on shares of argenx from $478.00 to $533.00 and gave the company an “outperform” rating in a research note on Friday, July 12th. Oppenheimer raised shares of argenx from a “market perform” rating to an “outperform” rating and set a $546.00 price objective for the company in a research note on Tuesday, July 23rd. Finally, JPMorgan Chase & Co. upped their price objective on shares of argenx from $500.00 to $640.00 and gave the company an “overweight” rating in a research note on Friday, August 23rd. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $548.00.

Check Out Our Latest Stock Analysis on argenx

argenx Stock Performance

NASDAQ:ARGX opened at $536.70 on Monday. The stock’s 50 day moving average price is $527.60 and its 200 day moving average price is $448.91. argenx SE has a 52 week low of $327.73 and a 52 week high of $554.74. The company has a market capitalization of $31.90 billion, a P/E ratio of -94.82 and a beta of 0.63.

argenx (NASDAQ:ARGXGet Free Report) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $1.34. The firm had revenue of $489.43 million for the quarter, compared to the consensus estimate of $436.66 million. argenx had a negative return on equity of 7.33% and a negative net margin of 12.31%. During the same quarter in the prior year, the company posted ($1.69) earnings per share. As a group, sell-side analysts forecast that argenx SE will post -0.37 earnings per share for the current fiscal year.

argenx Company Profile

(Free Report)

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

Read More

Institutional Ownership by Quarter for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.